tbuckley/cabot-search huggingface dataset:
Prevention of posttransfusion hepatitis
Authors: C. A. Janeway
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Session 13: indolent lymphoma
Authors: V Leblond, J Lejeune, O Tournilhac, P Morel, M Dihuydy, C Dartigeas, M Malphette, B Royer, S Chevret, S Johnson, R Owen, M Federico, S Luminari, A Dondi, G Rossi, C Boccomini, F Raimondo, L Rigacci, A Carella, A Pulsoni, F Merli, L Arcaini, L Marcheselli, M Brugiatelli, U Vitolo, E Kimby, B ¨stenstad, P De Nully Brown, H Holte, H Hagberg, M Erlanson, O Linde, K Arnljots, M Nordstro, C Sundstro
Journal: Annals of Oncology (2011)
Lowered cost potential for hepatitis B vaccine
Authors: R. M. Craig
Journal: JAMA (1985)

A disheartening aspect of the development of the hepatitis B vaccine is its limited use. A high degree of immunoreactivity and disease prophylaxis has been demonstrated in field trials; however, the vaccine has been underutilized even in high-risk, knowledgeable groups, including health care workers. Elsewhere in this issue ofThe Journal, Alter et al<sup>1</sup>have shown that only 6% of hemodialysis patients and 32% of hemodialysis staff have received all three hepatitis B vaccinations. Aside from financial considerations, the latter group has not availed itself of the vaccine mostly probably due to a fear of contracting the acquired immunodeficiency syndrome (AIDS), despite evidence to the contrary. Indeed, in male homosexuals, those who received the vaccine seem to have a lower incidence of AIDS than those who did not receive the vaccine.<sup>2,3</sup>In other populations, especially in underdeveloped countries, the cost of the vaccine has been a major impediment
From the NIH: New tissue culture--fluorescent method speeds detection of herpes simplex virus
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosing Sarcoidosis
Authors: Robert H. Israel
Journal: JAMA (1979)

<h3>To the Editor.—</h3> Difficulties in diagnosing sarcoidosis are not uncommon when the chest roentgenogram is normal. This was well portrayed in a recent article by Browne et al (240:2654, 1978), who described five patients with bone marrow sarcoidosis yet whose chest roentgenograms were normal. One of their cases vividly demonstrates the delay that can occur in diagnosing sarcoidosis under this circumstance. Two recent cases emphasize this point. <h3>Report of Cases.—Case 1.—</h3> A 22-yearold man had had four weeks of nightly fevers and had lost 9 kg. His past medical history and findings from a review of systems, physical examination, and chest roentgenogram were normal. Dimming of vision in his right eye developed and was diagnosed as uveitis. Sarcoid was initially not considered because of his normal chest roentgenogram. Subsequently, pulmonary functions disclosed a single-breath diffusing capacity of 45% of predicted with normal lung volumes and flow rates. A
Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
Authors: Patrick G. O'Malley, Michael J. Arnold, Cathy Kelley, Lance Spacek, Andrew Buelt, Sundar Natarajan, Mark P. Donahue, Elena Vagichev, Jennifer Ballard-Hernandez, Amanda Logan, Lauren Thomas, Joan Ritter, Brian E. Neubauer, John R. Downs
Journal: Annals of Internal Medicine (2020)

In June 2020, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) released a joint update of their clinical practice guideline for managing dyslipidemia to reduce cardiovascular disease risk in adults. This synopsis describes the major recommendations.On 6 August to 9 August 2019, the VA/DoD Evidence-Based Practice Work Group (EBPWG) convened a joint VA/DoD guideline development effort that included clinical stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions, systematically searched and evaluated the literature (English-language publications from 1 December 2013 to 16 May 2019), and developed 27 recommendations and a simple 1-page algorithm. The recommendations were graded by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.This synopsis summarizes key features of the guideline in 7 crucial areas: targeting of statin dose (not low-density lipoprotein cholesterol goals), additional tests for risk prediction, primary and secondary prevention, laboratory testing, physical activity, and nutrition.
PTH-184 Push Enteroscopy Leads to a Change in Diagnosis in the Majority of Patients with Positive Coeliac Serology and Negative Duodenal Biopsy
Authors: R Willington, V Lashmar, K Benes, K Barnett, S Weaver, R McCrudden, T Smith, C Gordon, P Cilclitira, S McLaughlin
Journal: Gut (2013)

<h3>Introduction</h3> Coeliac disease is associated with significant morbidity, and is an underdiagnosed condition with an estimated prevalence of 1% in the UK population. Current British Society of Gastroenterology Society guidelines classify individuals with positive coeliac serology and negative duodenal biopsy to latent coeliac disease and do not recommend further investigation or the initiation of a gluten free diet. In our recent practise patients at our institution with a strong clinical suspicion of coeliac disease and negative duodenal biopsies following a gluten containing diet undergo a push enteroscopy with biopsies of the jejunum and duodenum and histological reassessment of the original duodenal biopsies before a diagnosis of latent coeliac disease is made. We aimed to investigate whether push enteroscopy and histological reassessment increased the diagnostic yield of coeliac disease. <h3>Methods</h3> We searched our prospective endoscopy database for all patients with positive EMA or TTG results but negative D2 biopsies, who had undergone enteroscopy for a possible diagnosis of coeliac disease since 2007. Data including serology, result of histological reassessment of duodenal biopsies and assessment of jejunal biopsies were recorded. <h3>Results</h3> 13 patients were identified; 4 (31%) were male, the median age was 45 (range 19–78). In all 13, EMA testing had been performed, of which 9 were positive (69%). In 9, TTG results were available, of which 9 were positive (100%). Following review of the original duodenal biopsies by a second pathologist, 7 (54%) of the 13 patients were re-classified to active coeliac disease; median Marsh grade of 1 (range 0–2) Of the remaining 6 patients, 5 (83%) had evidence of active coeliac disease on jejunal biopsy; median Marsh grade of 2 (range 0–3b). Review of the jejunal biopsies alone, without review of original duodenal biopsies, would have led to active coeliac disease being diagnosed in 12 (92%) of 13 patients. <h3>Conclusion</h3> In this small retrospective series of patients with positive coeliac serology and negative duodenal biopsies, repeat histological assessment and jejunal biopsy led to a change in diagnosis in 92% of patients. These findings are unlikely to be limited to our institution. Our findings support the recommendation that a diagnosis of latent coeliac disease should only be made following repeat histological assessment and enteroscopy with jejunal biopsy. <h3>Disclosure of Interest</h3> None Declared.
Queries and Minor Notes
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response
Authors: J. M. Gwaltney
Journal: JAMA (1967)

Rhinovirus illness in young adults was characterized by rhinorrhea, nasal obstruction, sneezing, and pharyngeal discomfort. Length of illness ranged from 1 to 33 days, with a median of 7.42 days; one fourth of the illnesses lasted two weeks. Nasal symptoms, hoarseness, and cough occurred more frequently with confirmed rhinovirus common colds than with illnesses from which rhinoviruses were not cultured. Significant neutralizing antibody responses were measured in 77% of 77 paired serum specimens from patients with rhinovirus illness; only 5% had homologous titers of 8 or more in the acute phase of illness. The findings support other data indicating that serum neutralizing antibody develops following the majority of rhinovirus illnesses and is important in preventing symptomatic rhinovirus infection.
Acid-Suppressive Medication and Hospital-Acquired Pneumonia
Authors: Tetsuji Fujita
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Authors: K Evoy, Howard Bauchner
Journal: JAMA (2018)

A ventilation strategy using low tidal volumes may limit pulmonary complications in patients receiving intensive care.The PReVENT Investigators randomized 961 patients without acute respiratory distress syndrome who were receiving invasive ventilation and found that a low tidal volume strategy did not result in a greater number of ventilator-free days than an intermediate tidal volume strategy.In an Editorial, Rubenfeld and Shankar-Hari discuss the challenges of achieving optimal tidal volumes in patients requiring invasive ventilation.
Analysis of impact of post-treatment biopsies in phase I clinical trials.
Authors: Randy F. Sweis, Mark J. Ratain
Journal: Journal of Clinical Oncology (2014)

2582 Background: It is commonly believed that post-treatment biopsies for pharmacodynamic biomarkers (PD-BM) positively impact drug development. We sought to determine the utility of PD-BM in phase I trials, based on their impact on subsequent studies. Methods: We identified publications on phase I clinical trials in oncology that incorporated a biomarker by searching PubMed using a broad search algorithm. Articles were restricted to 2003-2006 in order to allow adequate time for publication of subsequent trials citing the phase I trial. Articles covering pediatric populations, hematologic malignancies, topical/local therapies, gene therapy, immunotherapy, or radiation therapy were excluded. Characteristics of identified trials were analyzed and trials that included post-treatment biopsies were selected for further analysis. Citing articles were identified using PubMed and Google Scholar, and those articles were then reviewed. Fisher’s exact test was used to compare groups. Statistics were carried out using JMP 11.0.0. Results: We identified 2,136 publications on phase I trials in oncology from 2003 to 2006. The use of any biomarker, as defined by our search algorithm was found in 200 (9.4%) publications, including 22 with a PD-BM. None of those PD-BM studies included a pre-specified statistical plan for the biomarker analysis. Only one study described performance characteristics of the assay. The number of reported biomarker tests ranged from 1-12, but no study included a correction for multiple testing. A statistically significant result on the PD-BM was reported in 3 (14%) studies, which was more likely to occur in industry-sponsored studies (P=0.04). A biomarker conclusion and statement of impact on future studies was found in 17 (77%) and 9 (41%) studies, respectively. Articles reporting subsequent phase 2/3 trials cited 19 (86%) of these PD-BM studies, but none used prior biomarker results in regard to phase 2/3 dose or schedule. Only a minority of the citing publications (8, 36%) mentioned the prior PD-BM studies. Conclusions: The impact of post-treatment biopsies for pharmacodynamic biomarkers is of uncertain value for subsequent drug development. This issue requires further evaluation, given the risk and cost of such studies.
Subcutaneous xanthomatosis
Authors: C.B. ARCHER, D.E. SHARVILL, N.P. SMITH
Journal: British Journal of Dermatology (1990)

Journal Article Subcutaneous xanthomatosis Get access C.B. ARCHER, C.B. ARCHER St John's Hospital for Diseases of the Skin, London, U.K. Dr C.B.Archer, Department of Dermatology, Bristol Royal Infirmary, Bristol BS2 8HW. Search for other works by this author on: Oxford Academic Google Scholar D.E. SHARVILL, D.E. SHARVILL Kent and Canterbury Hospital, Canterbury, U.K. Search for other works by this author on: Oxford Academic Google Scholar N.P. SMITH N.P. SMITH St John's Hospital for Diseases of the Skin, London, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 123, Issue 1, 1 July 1990, Pages 107–112, https://doi.org/10.1111/j.1365-2133.1990.tb01830.x Published: 01 July 1990
The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan, GI-screen: Efficient identification of cancer genome alterations in advanced gastric cancer.
Authors: Shigenori Kadowaki, Kohei Shitara, Satoshi Yuki, Shuichi Hironaka, Takeshi Kato, Hiroki Hara, Takeshi Kajiwara, Naoki Izawa, Satoru Iwasa, Toshikazu Moriwaki, Daisuke Naruge, Taito Esaki, Hiroshi Saeki, Toshihiro Kudo, Haruhiko Cho, Takao Tamura, Hiromichi Ebi, Shogo Nomura, Atsushi Ohtsu, Takayuki Yoshino
Journal: Journal of Clinical Oncology (2017)

4041 Background: We have conducted the Nationwide Cancer Genome Screening Project in Japan since April 2015 using Next Generation Sequencing in advanced non-colorectal gastrointestinal (GI) cancer (aNon-CRC), called as the SCRUM-Japan GI-SCREEN. Methods: This study is ongoing with 20 major cancer centers. Patients with aNon-CRC, who plan to or receive chemotherapy were eligible. DNA and RNA were extracted from FFPE tumor samples and were analyzed by the Oncomine Cancer Research Panel (OCP) which allows to detect gene mutation, copy number variant (CNV) and fusions across 143 genes in a CLIA certified CAP accredited laboratory. The detected genomic variant data were classified according to whether genetic drivers of cancer including gain- and loss-of-function or single nucleotide variant based on the Oncomine Knowledgebase. In this presentation, we show the results of advanced gastric cancer (aGC) cohort. Results: As of October 31 st in 2016, a total of 565 aGC samples were analyzed. The sequence with the OCP was successfully performed in 425 (75.2%). Out of 475 patients except for the 90 patients in which precise data is not collected, the proportion of histology type is followed; intestinal type 44.6%, diffuse type 54.5%, other 0.6%, unknown 0.2%. Out of 406 samples of which results were available, the frequently detected mutations were TP53 (47.8%), PIK3CA (8.6%), KRAS (5.4%), SMAD4 (4.9%), TET2 (4.4%), APC (3.9%), ERBB2 (3.7%) and CNVs were ERBB2 (10.8%), CCNE1 (9.4%), KRAS (3.7%), ZNF217 (3.2%), FGFR2 (2.7%), and MET (2.5%). FGFR3-TACC3 fusion, WIPF2- ERBB2 fusion and EGFR vIII were detected in 2, 1, and 2 cases, respectively. Conclusions: This nationwide screening system is efficient to detect rare gene alterations in aGC. This novel knowledge provides an intriguing background to investigate new target approaches and represents a progress toward more precision medicine. Clinical trial information: UMIN000016344.
A SHORT SILVER IMPREGNATION METHOD FOR THE DEMONSTRATION OF SPIROCHAETA PALLIDA IN TISSUE
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BLUE SCLEROTICS AND BRITTLE BONES
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Where there is smog, there is ire
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal